Scinai Immunotherapeutics Ltd ADR (SCNI) Stock Price, Quote & News

Company Profile

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufac...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 8 930 2529

Fax: 972 8 930 2531

Website: www.scinai.com

Address:

Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus, Jerusalem, Israel

OfficialStocktwitsUser Mar. 13 at 3:47 PM

$SCNI RSI: 48.26, MACD: -0.0320 Vol: 0.06, MA20: 0.79, MA50: 0.84 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

mikeduel123 Mar. 10 at 10:51 PM

$QNCX $SCNI

0 · Reply

StaceySol Mar. 6 at 8:18 PM

$QNCX $SCNI oh em gee 🚀🚀🚀🚀

0 · Reply

mikeduel123 Mar. 6 at 6:52 PM

$QNCX 🚨🚨🚨🚨🚨🚨WOW We should be hearing news about the EIB DEBT RESTRUCTURE in the next week LOOK AT THE PAST! $SCNI received Nadaq delisting letter on May 24, 2024 About three weeks later they had terms to RESTRUCTURE the EIB debt into equity. We are in a somewhat similar situation and need this debt restructured ASAP THIS IS HUGE!!!!! LFG think we skyrocket next week I'm buying 50c lotto calls a couple months out

1 · Reply

TheRealShortSqueezy Mar. 6 at 2:40 PM

$SCNI: Can the March 2 News Spark the Next Move? March 2 News: Scinai Immunotherapeutics announced it amended its PinCell acquisition option and submitted a revised €12M non-dilutive grant application to advance the PC111 antibody program, with a funding decision expected in 3–4 months. 📊 Technical view: ▪️ Major support: ~$0.80 ▪️ Price stabilizing near range lows ▪️ Short-term bounce forming 📈 Reclaim levels to watch: ▪️ $0.97 first resistance ▪️ $1.12 next breakout level ▪️ $1.31 supply zone ▪️ $1.54–$1.63 major resistance ▪️ $1.96+ momentum breakout If support holds and volume builds, SCNI could attempt a trend reversal from this base. 📈 Sector Peers: $BNTX $MRNA $REGN $AMGN

0 · Reply

BullTradeFinder Mar. 6 at 2:34 PM

$SCNI Volume spike here, watching for a $1+ break!

0 · Reply

focafoca99 Mar. 2 at 8:57 PM

$SCNI chasing €12M non-dilutive funding and moving PC111 closer to human PoC. Less dilution risk is always good.

0 · Reply

StockNews_Live Mar. 2 at 2:21 PM

$SCNI Scinai Immunotherapeutics Ltd. announced the execution of a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., and the submission of a revised application under th…

0 · Reply

Stock_Catcher Mar. 2 at 2:20 PM

$SCNI Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

0 · Reply

Bulltrader988 Feb. 25 at 1:46 PM

$SCNI 👃👀 https://www.stocktitan.net/news/SCNI/scinai-announces-expanded-israel-innovation-authority-support-for-nppn8ubnvto4.html

0 · Reply

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Feb 25, 2026, 8:11 AM EST - 18 days ago

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

Feb 17, 2026, 7:00 AM EST - 26 days ago

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

Jan 7, 2026, 7:00 AM EST - 2 months ago

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Dec 2, 2025, 8:50 AM EST - 3 months ago

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

Oct 6, 2025, 7:30 AM EDT - 5 months ago

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Sep 2, 2025, 7:30 AM EDT - 6 months ago

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Jul 29, 2025, 7:15 AM EDT - 8 months ago

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Jun 12, 2025, 8:00 AM EDT - 9 months ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 5, 2025, 9:00 AM EDT - 10 months ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

May 30, 2025, 7:00 AM EDT - 10 months ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 7, 2025, 4:01 PM EDT - 11 months ago

Scinai Announces Annual Financial Results for 2024

May 1, 2025, 7:00 AM EDT - 11 months ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Mar 27, 2025, 9:25 AM EDT - 1 year ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Mar 5, 2025, 7:30 AM EST - 1 year ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Jan 6, 2025, 7:31 AM EST - 1 year ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Dec 16, 2024, 9:25 AM EST - 1 year ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 5, 2024, 8:25 AM EST - 1 year ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 1 year ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 22, 2024, 7:15 AM EST - 1 year ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Oct 31, 2024, 6:59 AM EDT - 1 year ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 9, 2024, 11:12 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Aug 29, 2024, 6:31 AM EDT - 1 year ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 21, 2024, 8:45 AM EDT - 1 year ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 20, 2024, 2:28 PM EDT - 1 year ago

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 9:30 AM EDT - 1 year ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 15, 2024, 12:31 PM EDT - 1 year ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Jul 8, 2024, 8:14 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 3, 2024, 9:32 AM EDT - 1 year ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 2, 2024, 8:12 AM EDT - 1 year ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Jun 7, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

May 24, 2024, 4:01 PM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 15, 2024, 4:01 PM EDT - 1 year ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 6, 2024, 9:21 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Apr 10, 2024, 7:00 AM EDT - 2 years ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Scinai leadership to attend BIO-Europe Spring 2024

Feb 29, 2024, 8:45 AM EST - 2 years ago

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Jan 25, 2024, 10:26 AM EST - 2 years ago

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Jan 4, 2024, 4:01 PM EST - 2 years ago

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Jan 4, 2024, 6:15 AM EST - 2 years ago

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Dec 29, 2023, 9:21 AM EST - 2 years ago

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

OfficialStocktwitsUser Mar. 13 at 3:47 PM

0 · Reply

mikeduel123 Mar. 10 at 10:51 PM

$QNCX $SCNI

0 · Reply

StaceySol Mar. 6 at 8:18 PM

$QNCX $SCNI oh em gee 🚀🚀🚀🚀

0 · Reply

mikeduel123 Mar. 6 at 6:52 PM

1 · Reply

TheRealShortSqueezy Mar. 6 at 2:40 PM

0 · Reply

BullTradeFinder Mar. 6 at 2:34 PM

$SCNI Volume spike here, watching for a $1+ break!

0 · Reply

focafoca99 Mar. 2 at 8:57 PM

$SCNI chasing €12M non-dilutive funding and moving PC111 closer to human PoC. Less dilution risk is always good.

0 · Reply

StockNews_Live Mar. 2 at 2:21 PM

0 · Reply

Stock_Catcher Mar. 2 at 2:20 PM

$SCNI Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

0 · Reply

Bulltrader988 Feb. 25 at 1:46 PM

$SCNI 👃👀 https://www.stocktitan.net/news/SCNI/scinai-announces-expanded-israel-innovation-authority-support-for-nppn8ubnvto4.html

0 · Reply

Dieseld28 Feb. 25 at 1:25 PM

$SCNI Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform https://finance.yahoo.com/news/scinai-announces-expanded-israel-innovation-131100421.html

0 · Reply

Stock_Catcher Feb. 25 at 1:24 PM

$SCNI Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

0 · Reply

Biotech_Merchant Feb. 25 at 1:22 PM

$SCNI Another good headline for Scinai! Keep it going! https://finance.yahoo.com/news/scinai-announces-expanded-israel-innovation-131100421.html

0 · Reply

StockNews_Live Feb. 25 at 1:13 PM

$SCNI Scinai Immunotherapeutics Ltd. announced that its project to advance a robotic aseptic fill & finish platform has been approved for expanded support by the Israel Innovation Authority. The project wil…

0 · Reply

OfficialStocktwitsUser Feb. 25 at 3:56 AM

$SCNI RSI: 35.94, MACD: -0.0366 Vol: 0.11, MA20: 0.86, MA50: 0.85 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply